Among this list, the mAb adalimumab (ADA), a tumor necrosis factor-alpha (TNF-α) inhibitor used to treat rheumatoid arthritis and related disorders, was the most profitable product each year, generating global sales of approximately USD 62.6 billion between 2014 and 2017 [14]. This evidence concerns the gene TNF and rheumatoid arthritis.